Amy Boyd, MD
Allergy & Immunology · Gainesville, GANPI 1801099890
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.1% of the total across 371 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations.
Across 371 payments — averaging $21.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$1K
- GSK$968
- AstraZeneca$887
- Regeneron Healthcare Solutions, Inc.$833
- Pfizer$459
- Optinose US, Inc.$400
- plus $3K from 27 others
Across 1 payment — averaging $104.02 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$104
What the payments were for
- Consulting fees$170%
- Food & beverage$7,66398%
- Education$1342%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 39 | $1,085 |
| GSK | 66 | $968 |
| AstraZeneca | 50 | $887 |
| Regeneron Healthcare Solutions, Inc. | 30 | $833 |
| Pfizer | 27 | $459 |
| Optinose US, Inc. | 21 | $400 |
| Octapharma USA, Inc. | 7 | $351 |
| Kaleo, Inc. | 19 | $346 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $266 |
| CSL Behring | 8 | $208 |
| Boehringer Ingelheim | 10 | $194 |
| Grifols USA, LLC | 11 | $194 |
| Novartis | 8 | $177 |
| Amgen | 9 | $175 |
| Covis Pharma GmbH | 7 | $165 |
| Teva Pharmaceuticals USA, Inc. | 9 | $158 |
| Alk-abello, Inc | 7 | $152 |
| Biocryst US Sales Co., LLC | 5 | $118 |
| Blueprint Medicines Corporation | 4 | $118 |
| Eyevance Pharmaceuticals LLC | 4 | $78 |
| Pharming Healthcare, Inc. | 3 | $76 |
| Sanofi-aventis U.S. LLC | 1 | $75 |
| Mylan Specialty L.p. | 3 | $54 |
| Aimmune Therapeutics, Inc. | 2 | $50 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $43 |
| Merck | 2 | $36 |
| Sunovion Pharmaceuticals Inc. | 2 | $32 |
| Shire North American Group Inc | 1 | $26 |
| Biocryst Pharmaceuticals, Inc. | 1 | $20 |
| Cycle Pharmaceuticals Inc | 1 | $20 |
| Hikma Pharmaceuticals USA | 1 | $19 |
| ADMA Biomanufacturing LLC | 1 | $17 |
| AbbVie | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$125
How this compares
$7,813 in reported general payments places this provider in the 65th percentile of 107 allergy & immunology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 95 | $104,629 |
| XolairOmalizumab | 11 | $29,943 |
| Breo ElliptaFluticasone/Vilanterol | 47 | $21,307 |
| SymbicortBudesonide/Formoterol Fumarate | 21 | $7,498 |
| Advair HfaFluticasone Propion/Salmeterol | 11 | $4,956 |
| Epinephrine | 20 | $3,227 |
| Arnuity ElliptaFluticasone Furoate | 11 | $3,031 |
| RyaltrisOlopatadine Hcl/Mometasone | 11 | $2,735 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $2,553 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 96 | $2,387 |
| Ipratropium Bromide | 49 | $2,238 |
| Azelastine Hcl | 33 | $1,851 |
| Montelukast Sodium | 38 | $499 |
| Levocetirizine Dihydrochloride | 29 | $350 |
| Fluticasone Propionate | 24 | $330 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $968 | $128,966153 claims |
| AstraZenecaSymbicort | $887 | $7,49821 claims |
| Hikma Pharmaceuticals USAEpinephrine, Ryaltris | $19 | $5,96231 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 107 allergy & immunology providers in Georgia.
Other allergy & immunology in Gainesville
- Ronald BeebeGainesville$56K
- Kimberley ShanksGainesville$11K
- William NishGainesville$8K
- Faria KhanGainesville$7K
- Michael MaloneyGainesville$7K
- Michael BlaissRoswell$1.1M
- Deborah BirxAtlanta$470K
- Tracy BridgesAlbany$364K
- Jack EadesMacon$237K
- Stanley FinemanMarietta$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.